Organic & Biomolecular Chemistry

CORRECTION

View Article Online
View Journal | View Issue

Cite this: *Org. Biomol. Chem.*, 2017, **15**, 7977

Correction: Stereodivergent synthesis of right- and left-handed iminoxylitol heterodimers and monomers. Study of their impact on β-glucocerebrosidase activity

Fabien Stauffert,[a] Jenny Serra-Vinardell,[b] Marta Gómez-Grau,[b] Helen Michelakakis,[c] Irene Mavridou,[c] Daniel Grinberg,[b] Lluïsa Vilageliu,[b] Josefina Casas,[d] Anne Bodlenner,*[a] Antonio Delgado*[d,e] and Philippe Compain*[a]

DOI: 10.1039/c7ob90148h

rsc.li/obc

Correction for 'Stereodivergent synthesis of right- and left-handed iminoxylitol heterodimers and monomers. Study of their impact on β-glucocerebrosidase activity' by Fabien Stauffert *et al.*, *Org. Biomol. Chem.*, 2017, **15**, 3681–3705.

The authors regret that two references were omitted from the discussion concerning the heterodimeric concept and the role of the linker length in divalent inhibitors (pages 3682–3683).[1,2] The additional references are given below.

In addition, since examples of divalent inhibitors based on enantiomeric iminosugar heads have been previously reported,[1] the word 'unprecedented' should be deleted from the contents entry. The correct entry should read: "Janus-faced iminosugars act as pharmacological chaperones for the treatment of Gaucher disease."

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

References

1 Exploring the divalent effect in fucosidase inhibition with stereoisomeric pyrrolidine dimers: A. Hottin, D. W. Wright, E. Moreno-Clavijo, A. J. Moreno-Vargas, G. J. Davies and J.-B. Behr, *Org. Biomol. Chem.*, 2016, **14**, 4718.

2 Expanding the library of divalent fucosidase inhibitors with polyamino and triazole-benzyl bridged bispyrrolidines: A. Hottin, S. Carrión-Jiménez, E. Moreno-Clavijo, A. J. Moreno-Vargas, A. T. Carmona, I. Robina and J.-B. Behr, *Org. Biomol. Chem.*, 2016, **14**, 3212.

[a]*Laboratoire de Synthèse Organique et Molécules Bioactives (SYBIO), Université de Strasbourg/CNRS (UMR 7509), Ecole Européenne de Chimie, Polymères et Matériaux (ECPM), 25 rue Becquerel, 67087 Strasbourg, France. E-mail: philippe.compain@unistra.fr, annebod@unistra.fr*

[b]*Departament de Genètica, Microbiologia i Estadística, Universitat de Barcelona (UB), IBUB, IRSJD, CIBER de Enfermedades Raras (CIBERER), Av. Diagonal 645, E-08028 Barcelona, Spain*

[c]*Department of Enzymology and Cellular Function, Institute of Child Health, Athens, 11527, Greece*

[d]*Research Unit on BioActive Molecules (RUBAM), Departament de Química Biomèdica, Institut de Química Avançada de Catalunya (IQAC-CSIC), Jordi Girona 18, 08034 Barcelona, Spain. E-mail: delgado@rubam.net*

[e]*Unit of Pharmaceutical Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy, University of Barcelona (UB), Avga. Joan XXIII s/n, E-08028 Barcelona, Spain*